Etravirine induced severe hypersensitivity reaction and fulminant hepatitis: A case report and review of the literature

Journal of AIDS and Clinical Research

Volumn 3, Issue SPL ISSUE2, 2012, Pages

  Nabha, Linda ^a   Balba, Gayle P ^a   Tuazon, Carmelita ^b   Kumar, Princy N ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

^b GEORGE WASHINGTON UNIVERSITY HOSPITAL   (United States)

Author keywords

Antiretrovi ral therapy; Drug hypersensitivity; Etravirine; Hepatitis; Human immunodeficiency virus

Indexed keywords

EID: 84879834967     PISSN: None     EISSN: 21556113     Source Type: Journal    
DOI: 10.4172/2155-6113.S2-005     Document Type: Article

References (19)

1. Katlama C, Clotet B, Mills A, Trottier B, Molina JM, et al. (2010) Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials. Antivir Ther 15: 1045-1052.
2. Madruga JV, Cahn P, Grinsztejn B, Haubrich R, Lalezari J, et al. (2007) Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomized, double-blind, placebo-controlled trial. Lancet 370: 29-38.
3. Tibotec Therapeutics (2009) Letter: Safety update to the Severe Skin Reactions WARNINGS AND PRECAUTIONS section (5.1) of the INTELENCE. Highlights of prescribing information.
4. U.S. Food and Drug Administration (2009) MedWatch The FDA Safety Information and Adverse Event Reporting Program, Intelence (etravirine).
5. Bocquet H, Bagot M, Roujeau JC (1996) Drug-Induced Pseudolymphoma and Drug Hypersensitivity Syndrome (Drug Rash with Eosinophilia and Systemic Symptoms: DRESS). Semin Cutan Med Surg 15: 250-257.
6. Rojeau J (2005) Clinical heterogeneity of drug hypersensitivity. Toxicology 209: 123-129.
7. Chu KM, Boulle AM, Ford N, Goemaere E, Asselman V, et al. (2010) Nevirapine-Associated Early Hepatotoxicity: Incidence, Risk Factors, and Associated Mortality in a Primary Care ART Programme in South Africa. PLoS One 5: e9183.
8. Davis M, Shearer WT (2008) Diagnosis and Management of HIV Drug Hypersensitivity. J Allergy Clin Immunol 121: 826-832.
9. Patel SM, Johnson S, Belknap SM, Chan J, Sha BE, et al. (2004) Serious adverse cutaneous and hepatic toxicities associated with nevirapine use by non-HIV-infected individuals. J Acquir Immune Defic Syndr 35: 120-125.
10. Dona C, Soriano V, Barreiro P, Jiménez-Náchera I, González-Lahoz J (2000) Toxicity associated to efavirenz in HIV-infected persons enrolled in an expanded access program. Med Clin (Barc) 115: 337-338.
11. Borras-Blasco J, Navarro-Ruiz A, Borrás C, Casterá E (2008) Adverse cutaneous reactions associated with the newest antiretroviral drugs in patients with human immunodeficiency virus infection. J Antimicrob Chemother 62: 879-888.
12. Ogedegbe AO, Sulkowski MS (2003) Antiretroviral-associated liver injury. Clin Liver Dis 7: 475-499.
13. Miljkovic MM, Dobric S, Dragojevic-Simic V (2011) Consistency between causality assessments obtained with two scales and their agreement with clinical judgments in hepatotoxicity. Pharmacoepidemiol Drug Saf 20: 272-285.
14. Benichou C, Danan G, Flahault A (1993) Causality assessment of adverse reactions to drugs--II. An original model for validation of drug causality assessment methods: case reports with positive rechallenge. J Clin Epidemiol 46: 1331-1336.
15. Fleischbein E, O'Brien J, Martelino R, Fenstersheib M (2008) Elevated alkaline phosphatase with raltegravir in a treatment experienced HIV patient. AIDS 22: 2404-2405.
16. U.S. Food and Drug Administration (2009) MedWatch The FDA Safety Information and Adverse Event Reporting Program, Isentress (raltegravir).
17. Croce F, Vitello P, Dalla Pria A, Riva A, Galli M, et al. (2010) Severe raltegravir-associated rhabdomyolysis: a case report and review of the literature. Int J STD AIDS 21: 783-785.
18. Sulkowski M (2004) Drug-Induced Liver Injury Associated with Antiretroviral Therapy that Includes HIV-1 Protease Inhibitors. Clin Infect Dis 38: S90-S97.
19. Bohan KH, Mansuri TF, Wilson NM (2007) Anticonvulsant hypersensitivity syndrome: implications for pharmaceutical care. Pharmacotherapy 27: 1425-1439.